Skip to main content

Survival Outcomes by Extent of Repeat Surgery in Patients With Ipsilateral Breast Tumor Recurrence

In brief

In 311 patients, repeat lumpectomy showed similar survival to mastectomy

In this single-institution study, patients treated for breast cancer recurring in the same breast had no significant difference in overall or breast cancer-specific survival after repeat lumpectomy versus mastectomy. Repeat lumpectomy patients were selected differently, and local re-recurrence remained a concern, especially after prior radiation; the findings support considering it for appropriate patients, not assuming equal local control.

Journal
The Journal of surgical research (Q1)
Published
17 November 2026
Study design
Unclassified
Evidence level
Level 5, Expert Opinion (CEBM 5)
Authors
Jeana Chun, Samantha M Thomas, Akiko Chiba, Maggie L DiNome, Gayle A DiLalla, E Shelley Hwang, et al.
PMID
43044525
DOI
10.1016/j.jss.2026.10.002

Why clinicians should know about it

  • Picked for Breast and Endocrine Surgery (paper of the day, 19 November 2026): Repeat lumpectomy versus mastectomy for ipsilateral breast recurrence

Abstract

INTRODUCTION: The current guidelines generally favor mastectomy for ipsilateral breast tumor recurrence (IBTR) following prior lumpectomy with radiation therapy (RT), despite limited evidence demonstrating a survival advantage. We compared survival outcomes for patients with IBTR undergoing repeat lumpectomy versus mastectomy. METHODS: We identified patients with IBTR and no distant metastases following initial lumpectomy with or without RT treated at a single institution between 1984 and 2025. Patients were grouped by recurrence surgery: repeat lumpectomy versus mastectomy. Characteristics, treatment, and outcomes were compared. Overall survival and breast cancer-specific survival were evaluated from initial diagnosis and recurrence. RESULTS: A total of 311 patients with IBTR were included. Of those, 97 (31.2%) underwent repeat lumpectomy and 214 (68.8%) underwent mastectomy. Compared with mastectomy, repeat lumpectomy patients were older (median age 62 y [IQR 51-73] versus 55 y [46-66], P < 0.001). They were also more likely to have hormone receptor-positive disease and low-grade tumors. Mastectomy patients were more likely to have received prior radiation and chemotherapy. At a median follow-up of 11.5 y, there were no significant differences in overall survival or breast cancer-specific survival between groups. Among previously irradiated patients, local re-recurrence rates following repeat lumpectomy appeared lower with repeat RT than without repeat RT, although rates remained higher than those observed following mastectomy. CONCLUSIONS: Among patients who developed IBTR following initial lumpectomy, survival outcomes were similar between repeat lumpectomy and mastectomy. These findings support consideration of repeat lumpectomy in appropriately selected patients while acknowledging an increased risk of local re-recurrence particularly among previously irradiated individuals.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.